Nicox (FRA:NXOA) Debt-to-Asset : 0.48 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Nicox Debt-to-Asset?

Nicox's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Nicox's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €25.15 Mil. Nicox's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €52.98 Mil. Nicox's debt to asset for the quarter that ended in Dec. 2023 was 0.47.

Nicox Debt-to-Asset Historical Data

The historical data trend for Nicox's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Debt-to-Asset Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.09

0.13

0.19

0.34

0.48

Nicox Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.19	0.22	0.34	0.26	0.48

Competitive Comparison of Nicox's Debt-to-Asset

For the Biotechnology subindustry, Nicox's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nicox's Debt-to-Asset falls into.

Nicox Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nicox's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	25.153)	/	52.98
	=	0.47

Nicox's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	25.153)	/	52.98
	=	0.47

Nicox (FRA:NXOA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nicox Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nicox's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (FRA:NXOA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NICXF:USA ALCOX:France

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (FRA:NXOA) Headlines

No Headlines